| 21050 |
Baricitinib |
Olumiant® |
Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy. |
Rapid Review complete |
16th December 2021 |
 |
| - |
Baricitinib |
Olumiant® |
Treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Baricitinib may be used as monotherapy or in combination with methotrexate. |
Rapid Review complete |
13th July 2017 |
|
| 20056 |
Baricitinib |
Olumiant® |
Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy. |
Rapid Review complete |
28th January 2021 |
|
| - |
Bazedoxifene |
Conbriza® |
Treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of verterbral fractures has been demonstrated; efficacy on hip fractures has not been established. |
Rapid Review complete |
2nd January 2011 |
|
| 23037 |
Beclometasone /formoterol |
Fostair® |
Beclometasone / formoterol (Fostair®) for COPD. HTA ID 23037 Symptomatic treatment of patients with severe chronic obstructive pulmonary disease [COPD] (forced expiratory volume [FEV1] <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. |
Rapid Review Complete |
20th July 2023 |
|
| 23033 |
Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide |
Trimbow® |
Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide (Trimbow®) is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disorder (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA) or a combination of a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA). |
Rapid Review Complete |
19th July 2023 |
|
| 23034 |
Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide |
Trimbow® |
Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide (Trimbow®) for the maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year |
Rapid Review Complete |
19th July 2023 |
|
| 23038 |
Beclometasone/formoterol |
Fostair® |
Beclometasone/formoterol (Fostair®) is indicated for the regular treatment of asthma where use of a combination product (inhaled corticosteroid [ICS] and long-acting beta2-agonist [LABA]) is appropriate: -in patients not adequately controlled with ICS and 'as needed' inhaled rapid-acting beta2-agonist; or -in patients already adequately controlled on both ICS and LABA. |
Rapid Review Complete |
20th July 2023 |
|
| - |
Bedaquiline |
Sirturo® |
For use as part of an appropriate combination regimen for pulmonary MDR‑TB in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents. |
Rapid Review complete |
20th February 2015 |
|
| - |
Belatacept |
Nulojix® |
In combination with corticosteroids and a mycophenolic acid (MPA), for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen. |
Rapid Review complete |
23rd January 2012 |
|
| - |
Belimumab |
Benlysta® |
As add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy. |
Rapid Review complete |
31st August 2011 |
|
| 23021 |
Belimumab |
Benlysta® |
Belimumab is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis. |
Rapid Review Complete |
16th May 2023 |
|
| 23022 |
Belimumab |
Benlysta® |
Belimumab is indicated as add-on therapy in patients aged five years and older with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy. |
Rapid Review Complete |
29th May 2023 |
|
| 20026a |
Bempedoic acid |
Nilemdo® |
In adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet: In combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, OR Alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated |
NCPE Assessment process complete |
16th November 2021 |
|
| 20026b |
Bempedoic acid/Ezetimibe |
Nustendi® |
In adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet (a) in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe (b) alone in patients who are either statin – intolerant or for whom a statin is contraindicated and are unable to reach LDL-C goals with ezetimibe alone and (c) in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without a statin. |
NCPE Assessment Process Complete |
16th November 2021 |
|
| - |
Bendamustine |
Levact® |
Treatment of Chronic Lymphocytic Leukaemia (CLL) |
NCPE Assessment Process Complete |
20th November 2012 |
|
| - |
Benralizumab |
Fasenra® |
As add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists. |
Rapid Review complete |
14th February 2018 |
|
| 20018 |
Benralizumab |
Fasenra® |
As an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists. |
Rapid Review complete |
28th April 2020 |
|
| 22031 |
Berotralstat |
Orladeyo® |
Routine prevention of recurrent attacks of hereditary angioedema in adult and adolescent patients aged 12 years and older |
Awaiting full HTA submission from Applicant |
28th March 2023 |
|
| - |
Bezlotoxumab |
Zinplava® |
Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI. |
Rapid Review complete |
14th June 2017 |
|
| - |
Bictegravir/emtricitabine/tenofovir alafenamide |
Biktarvy® |
Treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components. |
Rapid Review complete |
7th June 2018 |
|
| - |
Bilastine |
Drynol® |
Symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria. |
Rapid Review complete |
23rd March 2011 |
|
| 23075 |
Bimekizumab |
Bimzelx® |
Bimekizumab (Bimzelx®) is indicated alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs |
Rapid Review Complete |
21st December 2023 |
|
| 21052 |
Bimekizumab |
Bimzelx® |
Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
Rapid Review complete |
6th July 2023 |
|
| - |
Blinatumomab |
Blincyto® |
Treatment of adults with Philadelphia chromosome negative (Ph-) relapsed or refractory B-precursor acute lymphoblastic leukaemia. |
NCPE Assessment Process Complete |
16th April 2018 |
|
| - |
Blinatumomab |
Blincyto® |
As monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (BCP-ALL) in first or second complete remission with minimal residual disease greater than or equal to 0.1%. |
Rapid Review complete |
23rd September 2019 |
|
| - |
Blinatumomab |
Blincyto® |
Treatment of paediatric patients aged 1 year and older with Philadelphia chromosome negative B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation |
Rapid Review complete |
30th January 2019 |
|
| 21031 |
Blinatumomab |
Blincyto® |
Treatment of paediatric patients (aged 1 year plus) with high-risk first-relapsed Ph- CD19+ B-precursor acute lymphoblastic leukaemia as part of consolidation therapy. |
Rapid Review complete |
3rd August 2021 |
|
| - |
Boceprevir |
Victrelis® |
As add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1. |
NCPE Assessment Process Complete |
17th January 2012 |
|
| - |
Bosentan |
Tracleer® |
Treatment pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO Functional Class (FC) III and WHO FC II. It is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease. |
Rapid Review complete |
8th July 2014 |
|
| - |
Bosutinib |
Bosulif® |
Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. |
Rapid Review complete |
25th September 2013 |
|
| - |
Brentuximab vedotin |
Adcetris® |
Treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and is also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma. |
NCPE Assessment Process Complete |
11th April 2014 |
|
| - |
Brentuximab vedotin |
Adcetris® |
Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy (license extension). |
Rapid Review complete |
6th March 2018 |
|
| 19058 |
Brentuximab vedotin |
Adcetris® |
Treatment of adult patients with CD30+ Hodgkin’s lymphoma at increased risk of relapse or progression following autologous stem cell transplant. |
NCPE Assessment Process Complete |
22nd October 2021 |
|
| 21010 |
Brentuximab vedotin |
Adcetris® |
In combination with cyclophosphamide [C], doxorubicin [H] and prednisone [P] (CHP) in combination for use in adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL). |
Rapid Review complete |
23rd April 2021 |
|
| 23045 |
Brexucabtagene Autoleucel |
Tecartus® |
Adults 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia |
Full HTA submission received from Applicant |
18th January 2024 |
|
| - |
Brigatinib |
Alunbrig® |
As monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib. |
Rapid Review complete |
11th December 2018 |
|
| 20031 |
Brigatinib |
Alunbrig® |
As monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK-inhibitor. |
Rapid Review complete |
6th August 2020 |
|
| - |
Brimonidine |
Mirvaso® |
Treatment of facial erythema of rosacea in adult patients. |
Rapid Review complete |
7th May 2014 |
|
| - |
Brivaracetam |
Briviact® |
As adjunctive therapy in the treatment of partial-onset seizures (POS) with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. |
Rapid Review complete |
22nd March 2016 |
|
| - |
Brodalumab |
Kyntheum® |
Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. |
Rapid Review complete |
29th August 2017 |
|
| 20009 |
Brolucizumab |
Beovu® |
Treatment of neovascular (wet) age-related macular degeneration. |
Rapid Review complete |
7th April 2020 |
|
| - |
Budesonide |
Jorveza® |
Treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age). |
Rapid Review complete |
26th May 2020 |
|
| 22067 |
Bulevirtide |
Hepcludex® |
Chronic hepatitis delta (CHD) infection in plasma (or serum) HDV RNA-positive adult patients with compensated liver disease. |
NCPE Assessment Process Complete |
22nd February 2024 |
|
| 22037 |
Buprenorphine/Naloxone |
Zubsolv® |
As substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who agreed to be treated for addiction. |
Rapid Review complete |
21st June 2022 |
|
| 22056 |
Buprenorphine |
Buvidal® |
Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over. |
Rapid Review complete |
23rd September 2022 |
|
| - |
Buprenorphine/Naloxone |
Suboxone® |
Management of opiate addiction |
NCPE Assessment Process Complete |
22nd May 2014 |
|
| - |
Burosumab |
Crysvita® |
Treatment of X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons. |
NCPE Assessment Process Complete |
12th March 2020 |
|
| 23005 |
Burosumab |
Crysvita® |
Burosumab (Crysvita®) is indicated for X-linked hypophosphataemia in adult patients. |
NCPE assessment ongoing |
24th April 2024 |
|
